Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PLUR vs SCNI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SCNI Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–3 Matrix Metrics)

SCNI Overall Winner 6-Pillar Tally: PLUR 0 – 4 SCNI (2 Tie) Matrix Metrics: PLUR 3 – 7 SCNI

As of Nov 17, 2026, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas SCNI carries 47.3/100 (HOLD) at $0.38 (N/M Forward P/E, -276.1% operating margin).

  • Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile SCNI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLUR vs SCNI
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08
SCNI NASDAQ Head-to-Head Winner
Scinai Immunotherapeutics Ltd. American Depositary Shares
Biological Products, (No Disgnostic Substances)
$0.38
-5.89% 1D
Market Cap $1.1M
TTM Revenue $3.1M
Forward P/E N/M
Beta / 30D Vol 3.85β · 82% Vol
Unified Composite Score
47.3 / 100 HOLD
Tech 43.0 Fund 42.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.2%), weak momentum, RSI 29
RSI-14: 29.0 · SMA20: $0.49 · SMA50: $1.04

6-Pillar Scorecard Institutional Category Breakdown (PLUR 0 – 4 SCNI)

Columns: Metric · PLUR · SCNI
1. Valuation Multiples SCNI
Forward P/E 3.6x N/M
Trailing P/E 3.6x 0.1x
PEG Ratio N/M N/M
EV / Revenue 44.6x 0.3x
2. Growth & Scale SCNI
Revenue Growth (YoY) -15.8% +572.5%
Earnings Growth (YoY) +0.0% +87.2%
TTM Revenue (USD) $1.0M $3.1M
Market Cap $15.1M $1.1M
3. Profitability & Quality SCNI
Gross Margin 44.6% N/A
Operating Margin -2454.5% -276.1%
Net Profit Margin 0.0% -80.1%
Return on Equity (ROE) -1022.0% -26.1%
4. Balance Sheet & Cash Flow SCNI
Cash Generation (TTM) -$22M -$6.5M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $30M Net Debt $3.76 Book/Sh · -26.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLUR (3) vs SCNI (7)
Institutional Metric PLUR SCNI Criterion Row Edge
Market Capitalization
Scale
$15.1M $1.1M Larger Scale PLUR
Trailing P/E Ratio
Valuation
3.6x 0.1x Lower Multiple SCNI
Forward P/E Ratio
Valuation
3.6x N/M Lower Multiple PLUR
Revenue Growth (YoY)
Growth
-15.8% +572.5% Higher Growth SCNI
Operating Margin (TTM)
Profitability
-2454.5% -276.1% Higher Margin SCNI
Net Profit Margin
Profitability
0.0% -80.1% Higher Margin PLUR
Return on Equity (ROE)
Capital Efficiency
-1022.0% -26.1% Higher ROE SCNI
52-Week Range Position
Momentum
2% ($1–$5) 5% ($0–$4) Stronger Trend SCNI
Beta / 30D Volatility
Risk Regime
0.80β · 102% Vol 3.85β · 82% Vol Lower Realized Risk SCNI
Unified Institutional Score
Composite Signal
28.8 / 100 (SELL) 47.3 / 100 (HOLD) Higher Composite SCNI
Trailing 12M Revenue (USD)
Operating Scale
$1.0M $3.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 44.6x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M ($30M Net Debt) -$6.5M EBITDA ($3.76 Book/Sh · -26.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +60.38 pp
PLUR: +11.09% · SCNI: -49.29%
3M Horizon SCNI +85.14 pp
PLUR: -46.34% · SCNI: +38.8%
6M Horizon SCNI +37.37 pp
PLUR: -62.52% · SCNI: -25.15%
1Y Horizon SCNI +14.4 pp
PLUR: -75.53% · SCNI: -61.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLUR vs SCNI. Trailing 12-month operating profitability (PLUR -2454.5% vs SCNI -276.1%) and valuation multiples (PLUR 3.6x vs SCNI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PLUR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin44.6%
Op. Margin-2454.5%
ROE / Fwd P/E-1022.0% · 3.6x
SCNI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.1M
Gross MarginN/A
Op. Margin-276.1%
ROE / Fwd P/E-26.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SCNI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SCNI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SCNI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1M market capitalization and -276.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLUR vs SCNI Key Questions & Quantitative Answers

As of Nov 17, 2026, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas SCNI carries 47.3/100 (HOLD) at $0.38 (N/M Forward P/E, -276.1% operating margin). Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile SCNI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SCNI leads the Growth & Scale pillar: PLUR posts -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin), compared with SCNI at +572.5% YoY revenue growth and +87.2% YoY earnings growth on $3.1M TTM revenue (N/A gross margin, -276.1% operating margin). On trailing 12-month operating scale, PLUR generates $1.0M in USD-normalized revenue versus $3.1M for SCNI. In operating R&D and SG&A reinvestment, PLUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SCNI.

SCNI screens cheaper on headline valuation multiples. PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin), whereas SCNI trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUR (-1022.0% ROE) versus SCNI (-26.1% ROE) capital efficiency.

In options market volatility and institutional positioning, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk). By comparison, SCNI carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.85β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.